Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for Treatment-Naive Patients with PNH
Nuvectis Pharma, Inc. announced that its drug ciprocopan received marketing approval from the National Medicinal Products Administration of China for treating patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously used complement inhibitors. This marks the first global approval of a once-daily oral Complement Factor B inhibitor, offering convenience and potential therapeutic benefits.
Topics: biotech complement inhibitors pharmaceuticals PNH treatment